Identification of the New In Vivo Metabolites of Ilaprazole in Rat Plasma after Oral Administration by LC-MS: In Silico Prediction of the H+/K+-ATPase Inhibitor
Open Access
- 16 January 2021
- Vol. 26 (2), 459
- https://doi.org/10.3390/molecules26020459
Abstract
Ilaprazole is a proton pump inhibitor used to treat digestive diseases. In this study, blood samples were collected after oral administration of ilaprazole and prepared by liquid–liquid extraction. The metabolites of ilaprazole were detected by liquid chromatography–high-resolution mass spectrometry (LC-HRMS) and LC-MSn. A total of twelve in vivo metabolites were detected in rat plasma and six new metabolites of ilaprazole, including one reductive metabolite with sulfide (M3), two hydroxylated metabolites with sulfoxide (M7 and M8), and three oxidative metabolites with sulfone (M9, M11, and M12), were identified. The possible metabolic pathways of ilaprazole and the fragmentation behaviors of its metabolites were elucidated. The result of the in silico prediction indicates that all the new metabolites showed the potential ability to inhibit H+/K+-ATPase activity.Keywords
This publication has 19 references indexed in Scilit:
- Drug metabolism and metabolite safety assessment in drug discovery and developmentExpert Opinion on Drug Metabolism & Toxicology, 2018
- Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter studySurgical Endoscopy, 2018
- Ilaprazole for the treatment of gastro-esophageal refluxExpert Opinion on Pharmacotherapy, 2016
- Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in ChinaJournal of Medical Economics, 2016
- Modified sequential therapyvsquadruple therapy as initial therapy in patients withHelicobacterinfectionWorld Journal of Gastroenterology, 2015
- The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open‐label crossover studyAlimentary Pharmacology & Therapeutics, 2014
- Efficacy of ilaprazole in the treatment of duodenal ulcers: A meta-analysisWorld Journal of Gastroenterology, 2014
- Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5Xenobiotica, 2011
- Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypesClinica Chimica Acta; International Journal of Clinical Chemistry, 2008
- Effects of IY-81149, a Newly Developed Proton Pump Inhibitor, on Gastric Acid Secretion in vitro and in vivoArzneimittelforschung, 2001